Circulating tumour DNA (ctDNA) is transforming how we diagnose and treat complex cancers, particularly when clinical pathways ...

AUSTIN, Texas, February 10, 2025--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor ...

Exclusive: DNA test means patients could be offered most effective treatment first, boosting their chances of beating the disease ...

ctDNA offers a non-invasive way to track the progression of Multiple Myeloma, reducing the need for painful bone marrow biopsies Detects genetic mutations, treatment response, and early stage cancer ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...

This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care. "This milestone represents a transformative moment in ...

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today commented on recent updates by the NCCN on circulating tumor DNA (ctDNA) ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced new data showing that its whole-genome sequencing (WGS)-based ...

Data include findings generated using the RaDaR 1.0 assay to assess molecular residual disease and recurrence risk in early breast cancer NeoGenomics will present new data from the SURVIVE HERoes ...

A personalized blood test known as a circulating tumor DNA (ctDNA) test—which detects tiny fragments of cancer DNA ...